ABOUT LABYRX

LabyRx is a clinical-stage immuno-oncology company focused on developing the next-generation of novel therapeutic vaccines and antibody therapies to improve the lives of cancer patients worldwide.

​

Our lead product, LabVax, is a Labyrinthin-derived peptide vaccine that recruits the body's immune cells to attack adenocarcinoma tumors. It expands on the successful first-into-human clinical trial at the Chinese University of Hong Kong that used a vaccine prototype to the current LabVax.

​

LabVax has been approved by the US FDA for human clinical trials that are now being conducted in concert with the University of California, Davis and National Cancer Institute.